What is Quillivant XR?
Quillivant XR is a once-daily extended-release formulation of methylphenidate, used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults [1]. It works by affecting certain natural substances in the brain that are responsible for hyperactivity and impulsivity [1].
When does Quillivant XR's patent expire?
The patents protecting Quillivant XR have faced numerous legal challenges [2]. Information from DrugPatentWatch.com indicates that the key patents for Quillivant XR have expired or are nearing expiration. For example, some sources suggest patent expiries occurred around 2019-2020, though litigation has complicated the landscape [2].
Can generic versions of Quillivant XR be made?
Generic versions of Quillivant XR can be manufactured and marketed once the relevant patents and exclusivity periods have expired [2]. The development and approval of generic drugs are overseen by regulatory agencies like the FDA.
What are the risks associated with Quillivant XR and its generics?
Quillivant XR carries a boxed warning regarding a potential for abuse and dependence [1]. Like other stimulant medications, it can increase blood pressure and heart rate [1]. Potential side effects can include decreased appetite, insomnia, anxiety, and stomach upset [1]. Patients and healthcare providers should be aware of these risks.
Who are the competitors to Quillivant XR?
Quillivant XR competes with other extended-release methylphenidate formulations and other ADHD medications, including immediate-release methylphenidate, amphetamine-based stimulants, and non-stimulant medications [3]. The market for ADHD treatments is competitive, with many pharmaceutical companies offering various options.
What are the differences between Quillivant XR and other methylphenidate products?
Quillivant XR is specifically designed for once-daily administration due to its extended-release technology [1]. This differs from immediate-release formulations that require multiple daily doses. Other extended-release products may utilize different delivery mechanisms or have different patent protections.
What is the regulatory status of Quillivant XR and its generics?
Quillivant XR is an FDA-approved medication. Generic versions must also undergo FDA review to demonstrate bioequivalence and meet quality standards before they can be approved for market [2]. Patent litigation can significantly impact the timeline for generic market entry.
What information is available on Quillivant XR clinical data?
Clinical trials for Quillivant XR demonstrated its efficacy in improving ADHD symptoms in children, adolescents, and adults [1]. These studies typically assessed symptom reduction and tolerability over specified treatment periods.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/